Accelerating CB1, CB2 & Cannabinoid Approvals in Obesity, Pain, CNS & Inflammation
As drug developers continue to utilize the expedited FDA regulatory pathway available for CBD, alongside a growing interest in the therapeutic benefits and regulatory approval of novel cannabinoids, the cannabinoid drug development landscape is rapidly evolving. Additionally, innovative preclinical candidates targeting CB1 and CB2 receptors are advancing through the pipeline, as developers aim to secure regulatory approval for treatments addressing weight management, pain, neurological conditions, and more.
The field continues to grow, with both phytocannabinoid and synthetic drug candidates aspiring to achieve milestones like those set by Epidiolex, Marinol, Syndros, and Cesamet.
The 7th CB1, CB2, & Cannabinoid Drug Development Summit offers:
- Innovative Research Insights: Discover the latest advancements in cannabinoid and ECS-targeting research, highlighting breakthroughs in preclinical and clinical studies
- Expert Panels: Engage with 18+ expert speakers from top companies, sharing their latest research challenges and innovative approaches
- Regulatory Deep Dives: Participate in in-depth discussions on navigating the evolving regulatory landscape and securing approvals for cannabinoid therapies
- Success Stories: Examine case studies of successful cannabinoid drug developments and ongoing clinical trials, with a focus on efficacy and safety
- Trial Design Evaluations: Assess cutting-edge clinical trial designs, including considerations for safety, efficacy, and dosage
Join 60+ experts from discovery, preclinical, translational, regulatory, clinical, and chemistry fields as they work to unlock the potential of CB1, CB2, and cannabinoid drugs for treating obesity, pain, inflammation, CNS disorders, and rare diseases.
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Top Testimonials
“Non-commercial and highly professional. The attendees were all enthusiastic science-based professionals.”
William Beckman, Senior Vice President, Clinical Pharmacology
Gefion Canada
“Outstanding speakers, great additional knowledge gained.”
Andrew Mulchinski, Assoc Clinical Project Manager & Business Development Associate
Symbio
“The conference addressed the central issues challenging this emerging industry, where legality, science, and business continue to shape our futures. It is very exciting to be a part of this vibrant community.”
Andrea Small-Howard, President
GB Sciences
“Ability to interact in one place with leading prescription cannabinoid drug developers and vendors.”
James Mongiardo, Chief Executive Officer
Gefion Canada
“Great meeting to connect with top experts and companies in this field.”
Hang Ma, Associate & Assistant Professor – Research
University of Rhode Island
Proud to Partner With:
View Upcoming Events in the Series Here
